Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) EBT Margin (2016 - 2025)

Amicus Therapeutics filings provide 14 years of EBT Margin readings, the most recent being 1.7% for Q4 2025.

  • On a quarterly basis, EBT Margin fell 360.0% to 1.7% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.03%, a 547.0% increase, with the full-year FY2025 number at 0.03%, up 547.0% from a year prior.
  • EBT Margin hit 1.7% in Q4 2025 for Amicus Therapeutics, down from 20.27% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 20.27% in Q3 2025 to a low of 103.48% in Q1 2022.
  • Median EBT Margin over the past 5 years was 37.65% (2022), compared with a mean of 40.14%.
  • Biggest five-year swings in EBT Margin: plummeted -1554bps in 2022 and later surged 5204bps in 2023.
  • Amicus Therapeutics' EBT Margin stood at 97.74% in 2021, then increased by 19bps to 79.55% in 2022, then surged by 65bps to 27.51% in 2023, then surged by 119bps to 5.3% in 2024, then tumbled by -68bps to 1.7% in 2025.
  • The last three reported values for EBT Margin were 1.7% (Q4 2025), 20.27% (Q3 2025), and 12.4% (Q2 2025) per Business Quant data.